Gary Barnette

Company: Veru Inc.

Job title: Chief Scientific Officer

Bio:

Gary Barnette, Ph.D. is the Chief Scientific Officer of Veru. Prior to joining Veru, Dr. Barnette was Sr. Vice President of Scientific and Regulatory Affairs at Camargo Pharmaceutical Services, LLC, during which he oversaw the development of scientific and regulatory drug development strategies across all therapeutic areas for 6 years. From 2000 to 2012, Dr. Barnette served in various positions at GTx, Inc., including as Vice President, Clinical Development Strategy. Throughout his tenure at GTx, Dr. Barnette managed responsibilities across regulatory, clinical, clinical pharmacology, and medical affairs departments for urology (men’s health) and cancer supportive care. Prior to GTx, Dr. Barnette was a Clinical Pharmacology and Biopharmaceutics Reviewer at the U.S. FDA, where he received numerous awards for reviewing, mentoring, and serving on various FDA guidance development groups and initiative task forces. Dr. Barnette holds a Ph.D. in Basic Pharmaceutical Sciences (Clinical Pharmacology and Pharmacokinetics) from West Virginia University, School of Pharmacy.

Seminars:

Panel Discussion: Assessing Functional Readouts & Optimal Muscle-to-Fat Ratio to Redefine Success in Obesity Care to Improve Drug Performance 1:10 pm

Analyzing the critical need for functional readouts and clinically relevant endpoints beyond weight on a scale to accurately measure and demonstrate the benefits of muscle preservation in obesity treatment • Discussing the scientific and clinical consensus on how much muscle loss is too much, focusing on the optimal muscle-tofat ratio to guide therapeutic development and…Read more

day: Day One

Selective Androgen Receptor Modulation as a Mechanism for HighQuality Weight Loss and Muscle Preservation in Obesity 9:30 am

Selective androgen receptor modulation acts as a novel mechanism to preserve lean muscle mass during weight loss, leading to improved metabolic health and a healthier body composition By targeting the androgen receptor, this approach allows for preferential fat loss, ultimately preventing the muscle wasting often seen with traditional diets and weight loss drugs This strategy…Read more

day: Pre-Conference Day